Relmada Therapeutics Inc. Common Stock
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
RLMD Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$2.8900 |
Previous Close Volume |
93490 |
Latest News
- Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 09 Dec 2024 07:33:21
- Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance 04 Dec 2024 07:33:57
- Relmada Therapeutics to Present at Jefferies London Healthcare Conference 19 Nov 2024 09:03:21
- Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease 14 Nov 2024 07:33:36
- Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update 07 Nov 2024 16:19:13
- Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 04 Nov 2024 16:34:35
- Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update 07 Aug 2024 16:35:03
- Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024 05 Aug 2024 07:35:18
- Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry 18 Jun 2024 08:35:28
- Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference 10 Jun 2024 07:35:36
- Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference 03 Jun 2024 07:35:17
- Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results 08 May 2024 16:20:31
- Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 06 May 2024 07:50:28
- Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results 19 Mar 2024 16:21:07
- Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 12 Mar 2024 07:51:10
- Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference 05 Mar 2024 07:35:59